How Artificial Intelligence Can Enhance Epilepsy Management

By Staff Writer

February 13, 2024

Introduction

The application of artificial intelligence (AI) in healthcare is increasingly becoming a topic of interest, especially to detect diseases from pathology samples or imaging. In recognition of World Epilepsy Week, we take a look at 4 studies on developments made in AI use in epilepsy research and innovation, discussing how these may lead to improved outcomes for those living with one of the most common neurological disorders.

AI and Epilepsy Detection

The first study by Jin et al. discusses the use of machine learning in detecting Focal Cortical Dysplasia (FCD), a major cause of pharmacoresistant epilepsy in those undergoing surgical resection. The use of magnetic resonance imaging (MRI) is mostly used to detect these features, however, some FCD type II lesions are too subtle to be detected by conventional MRI scans. Finding a previously undiscovered lesion may change the surgical technique and improve seizure results. Using surface-based MRI morphometry coupled with machine learning, they were able to detect FCD with a sensitivity of 73.7% and specificity of 90.0% in this study. This method showed robust performance across different centres and scanners, suggesting AI’s potential as a valuable tool in presurgical evaluations for patients with pharmacoresistant epilepsy.

AI in Classifying Temporal Lobe Epilepsy

The second study explored in depth the use of AI in classifying Temporal Lobe Epilepsy (TLE). Gleichgerrcht et al. used support vector machine (SV) and deep learning (DL) models based on region of interest (ROI-based) structural and diffusion brain MRI data. The models showed better or similar (68–75%) performance in identifying TLE compared to lateralizing the side of TLE. The models performed more accurately for patients with hippocampal sclerosis (68–76%) than non-lesional patients (53–62%). Overall, the study demonstrated the potential of machine learning and AI in future epilepsy care, especially in TLE.

AI for Epileptic Seizure Prediction

The third study, Daoud and Bayoumi examined the use of deep learning in predicting epileptic seizures. Patients who suffer from epilepsy will experience a significant impact on their lives if they are able to anticipate the onset of seizures.The researchers developed a patient-specific seizure prediction technique based on deep learning and applied to long term scalp electroencephalogram (EEG). Four deep learning models were suggested as a method to improve classification accuracy and prediction time by extracting the most discriminative characteristics. The suggested method uses the convolutional neural network (CNN) to extract significant spatial data to predict seizures earlier than current methods. This approach yielded a high accuracy of 99.6% and a very early seizure prediction time, making it one of the most efficient methods for seizure prediction.

AI for Intracranial Interictal Epileptiform Discharges Detection

In the final study Quon and colleagues explored the use of deep learning in classifying intracranial interictal epileptiform discharges (IEDs). Epileptiform discharges that occur between seizures are known as IEDs and is also used in differentiating epilepsy types. Previous research has linked IEDs to memory loss, increased seizure frequency and recurrence, making IEDs clinically relevant. Human visual annotation of IEDs is the gold standard, however it takes time and training to classify EEG patterns correctly. The researchers developed an automated method, “AiED,” which combined a template-matching algorithm and a CNN. The method achieved comparable performance to human reviewers, suggesting its potential in supporting clinical and research EEG analyses by reducing time and resources spent.

Concluding remarks:

In conclusion these studies demonstrate the potential of AI in improving the detection and management of epilepsy. This will lead to improved accuracy, lower capacity demand on healthcare services and overall better outcome for patients living with epilepsy. As AI technology continues to evolve, its application in epilepsy management is likely to become even more significant.

Reference url

Recent Posts

340B Drug Pricing Lawsuit
      

Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA

🤔 How will ongoing legal battles shape the future of the 340B Drug Pricing Program?

Eli Lilly and Johnson & Johnson are challenging HRSA’s proposed rebate models, arguing that their approaches are essential for enhancing transparency and ensuring discounts directly benefit vulnerable patients. This crucial legal dispute highlights the tensions surrounding drug pricing regulations and could profoundly impact how discounts are provided to covered entities.

Dive into the details of these lawsuits and their implications for the pharmaceutical landscape.

#SyenzaNews #pharmaceuticals #healthcarepolicy #innovation #DrugPricing

WHO Investment Round 2023
    

WHO Investment Round: Securing Funding with Transparency Challenges

🌍 How can global health initiatives thrive with increased funding?

The WHO Investment Round is a pivotal initiative striving to secure $7.1 billion for essential health programs from 2025 to 2028. While achieving 53% of this target via diverse donor engagement, transparency in funding remains a challenge. Discover how these efforts can accelerate progress towards universal health coverage and tackle critical health issues like malaria and cervical cancer!

#SyenzaNews #globalhealth #universalhealthcoverage #healthcare #innovation

HPV vaccination South Africa
    

HPV vaccination South Africa: Cervical Cancer Prevention

🌍 How is South Africa leading the charge against cervical cancer?

Since launching its HPV vaccination program, the country has made remarkable strides in protecting future generations. With impressive coverage rates and a focus on at-risk populations, South Africa serves as a global model for effective public health strategies. Discover how this initiative not only combats cervical cancer but also addresses broader health concerns.

#SyenzaNews #HealthTech #GlobalHealth #HealthcareInnovation #CervicalCancer #HPVVaccination

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.